doi: 10.1503/cmaj.101281 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, type 2 diabetes, metformin, meta-analysis Citation Deng R, Mei K, Song T, Huang J, Wu Y, Yu P, Yan Z and Liu X (2024) First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
The post says discontinuing without a plan often leads to rebound weight gain and frustration, and argues for working with a provider on continuity, monitoring and lifestyle factors instead
Tirzepatide may offer added benefits for some patients by targeting both GLP-1 and GIP receptors
Reactive hypoglycemia in non-diabetics is a bit different
Manage the stress